top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

What’s Driving CD19 Cell Therapy to Autoimmune Disease?

Cell therapy offers a disease-modifying option for patients w/ refractory autoimmune disease.

Autoimmune disease is a major unmet need

  • Est. 7M patients in the U.S. with a form of B-cell mediated autoimmune disease (Canaccord Genuity, 2023)

Pathogenic B cells can drive systemic diseases via intrinsic/extrinsic factors.

The effectiveness of current therapies is inadequate:

  • Often consists of lifelong immune suppression

  • B-cell-directed agents have limited activity

Recent results with CD19 CAR-T in treating auto-immune diseases look promising

  • CD19-directed cell therapy is challenging the treatment paradigm for autoimmune diseases

  • Drug-free remissions after a single treatment in academic trials.

⇨ See below for Mackensen et al. 2022 and Muller 2023 results in lupus (FIG. 1 📸).

FIG. 1. CD19-directed Cell Therapy Potential (early results in autoimmune disease).

If you are interested in cell therapy companies, check out our comprehensive report featuring100’s of biopharma companies specializing in cell therapy products.

 Ideal for...

🔬 Contract Research Organizations

🧪 Contract Manufacturing Organizations

⚗️ Biopharma vendors looking for new opportunities

🧬 Biopharma professionals at cell & gene therapy companies

Article History:


This article is not investment or legal advice.


bottom of page